These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35234368)

  • 1. Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment.
    Goh KY; Lau KW; Cheng TY; Tham SC; Lim CT; Iyer NG; Lim SB; Lim DW
    Cancer Commun (Lond); 2022 Apr; 42(4):355-359. PubMed ID: 35234368
    [No Abstract]   [Full Text] [Related]  

  • 2. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
    Wu Q; Zhao Y; Wang P
    Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcription factors: a potential therapeutic target in head and neck squamous cell carcinoma.
    Pazhani J; Veeraraghavan VP; Jayaraman S
    Epigenomics; 2023 Jan; 15(2):57-60. PubMed ID: 36974620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.
    Granados-García M; Aguilar-Ponce JL; Maldonado-Magos F; De la Garza-Salazar JG
    ORL J Otorhinolaryngol Relat Spec; 2016; 78(6):320-333. PubMed ID: 28125819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
    Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
    Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the methylene blue mediated photodynamic therapy on
    Kahalian S; Koopaie M; Hakimiha N; Kolahdooz S
    Folia Med (Plovdiv); 2022 Apr; 64(2):221-228. PubMed ID: 35851773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
    Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
    Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
    Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
    Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
    Kim HR; Kang HN; Yun MR; Ju KY; Choi JW; Jung DM; Pyo KH; Hong MH; Ahn MJ; Sun JM; Kim HS; Kim J; Yoo J; Kim KR; Koh YW; Kim SH; Choi EC; Yoon SO; Shim HS; Paik S; Kim TM; Cho BC
    Br J Cancer; 2020 Dec; 123(12):1720-1729. PubMed ID: 32963347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
    In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC].
    Cserepes M; Nelhűbel GA; Meilinger-Dobra M; Surguta SE; Rásó E; Ladányi A; Kenessey I; Szöőr Á; Vereb G; Remenár É; Tóvári J
    Magy Onkol; 2021 Jun; 65(2):188-195. PubMed ID: 34081766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
    Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
    Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
    Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
    Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck.
    Mangano A; Mangano A; Lianos GD; Roukos DH; Caprioglio A; Dionigi G
    Future Oncol; 2015; 11(1):9-12. PubMed ID: 25572780
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices.
    Peria M; Donnadieu J; Racz C; Ikoli JF; Galmiche A; Chauffert B; Page C
    Head Neck; 2016 Apr; 38 Suppl 1():E911-5. PubMed ID: 25994489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma.
    Bredel M; Kim H; Bonner JA
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
    Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.
    Johansson AC; Ansell A; Jerhammar F; Lindh MB; Grénman R; Munck-Wikland E; Östman A; Roberg K
    Mol Cancer Res; 2012 Sep; 10(9):1158-68. PubMed ID: 22809838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.